Factory Direct Supply 99% Donepezil CAS No. 120014-06-4
| Price | USD5.99 |
| Packge | 1KG |
- Min. Order:1KG
- Supply Ability:100KG
- Time:2022-07-21
Product Details
- Product Namedonepezil
- CAS No.120014-06-4
- EINECS No.601-651-9
- MFC24H29NO3
- MW379.49
- AppearanceSolidWhite to Off-White
- Melting point 207°C
- Water Solubility 2.931 mg/L
- Boiling point 527.9±50.0 °C(Predicted)
- density 1.141±0.06 g/cm3(Predicted)
- storage temp. Sealed in dry,Room Temperature
| Chemical Name | Donepezil | ||
| Synonyms | 5,6-Dimethoxy-2,3-dihydro-1H-inden-1-one | ||
| CAS NO. | 120014-06-4 | Purity | 99% |
| Appearance | White powder | Application | Used for lab research |
| Molecular Formula | C24H29NO3 | Molecular Weight | 379.49200 |
| Boiling Point | 527.9ºC at 760mmHg | Melting Point | 207ºC |
| PSA | 38.77000 | LOGP | 4.29900 |
Casey
Whatsapp / WeChat: +8617320697543
Email:kai000@hktiansheng.com
https://www.chemicalbook.com/manufacturer/ExhibitionBooth525/
Company Profile Introduction
My name is Nancy, the export manager of Hong Kong Tiansheng New Material Trading Co., LTD. We specialize in the production and export of various chemical materials, pharmaceutical raw materials.
Recommended supplier
-
VIP1年
- AKASH PHARMA EXPORTS
- Donepezil 99%
- Inquiry
- 2024-05-16
-
VIP1年
- BEC Chemicals Pvt Ltd
- Donepezil 99%
- Inquiry
- 2024-03-30
-
VIP0年
- Ebenezer Industries
- Donepezil 98%
- Inquiry
- 2024-03-30
-
VIP1年
- Niksan Pharmaceutical
- 120014-06-4 99%
- Inquiry
- 2024-03-14
-
VIP1年
- Vijaya Pharma And Life Science
- 120014-06-4 98%
- Inquiry
- 2024-03-13
-
VIP1年
- Alfa Omega Pharma
- Donepezil 120014-06-4 98%
- Inquiry
- 2024-02-17
-
VIP1年
- Ralington Pharma
- Donepezil 98%
- Inquiry
- 2024-02-05
-
VIP1年
- Besil Chem LLP
- 120014-06-4 98%
- Inquiry
- 2024-01-29
-
VIP1年
- Zydus Lifesciences Ltd.
- 120014-06-4 Donepezil 98%
- Inquiry
- 2024-01-27
-
VIP1年
- neuland labs
- Donepezil 98%
- Inquiry
- 2023-12-30
- Since:2021-08-12
- Address: UNIT 1307，BEVERLEY COMMERCIAL,CENTRE,87-105 CHATHAM ROAD,SOUTH TSIM SHA TSUI，KLN,HONG KONG
INQUIRY